Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The HIVconsv gene was constructed by assembling the 14 most conserved regions of the HIV-1 proteome into one chimaeric protein. This gene has been inserted into 2 leading non-replicating vaccine vectors: an attenuated chimpanzee adenovirus serotype 63 (ChAdV63) and a modified vaccinia virus Ankara (MVA) to construct the ChAdV63.HIVconsv and MVA.HIVconsv HIV-1 candidate vaccines. The present study is named ChAd-MVA.HIVconsv-BCN01 and it is a phase I, multicenter primary/booster therapeutic vaccination study to evaluate the safety and immunogenicity of ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly according to a 0-8 weeks or a 0-24 weeks schedule to recently HIV-1 infected individuals with early viral suppression 6 months after initiation of Tenofovir/Emtricitabine plus Raltegravir.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

NCT01024842

HIV-1

TERMINATED PHASE1

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

NCT00107549

HIV Infections

COMPLETED PHASE1

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults

NCT01151319

HIV-1 Infections

COMPLETED PHASE1

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

NCT05208125

HIV Infection

COMPLETED PHASE1

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

NCT00083603

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is a Phase I, multicenter primary/booster therapeutic vaccination study to evaluate the safety and immunogenicity of ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly according to a 0-8 weeks or a 0-24 weeks schedule to recently HIV-1 infected individuals with early viral suppression 6 months after initiation of Tenofovir/Emtricitabine plus Raltegravir.

24 patients who meet all eligibility criteria will be enrolled, first 10 individuals will be assigned in the 0-24 week prime/boost regimen (ARM A). The next 10 volunteers will be assigned in the 0-8 week prime/boost regimen (ARM B).Four additional volunteers will be included as 'back-up' and assigned 2 in ARM A and 2 in ARM B to cover a possible 10% of patients who drop-off during the follow-up. Purpose of staging of 2 study arms is just to shorten overall study duration (from screening of first volunteer to 6 months after last immunisation of last volunteer).

Lastly, 24 patients who also meet all eligibility criteria will be enrolled as controls, will also initiate promptly antiretroviral treatment with Tenofovir/Emtricitabine plus Raltegravir but will not receive the investigational vaccines. Control patients will consecutively be assigned to the 0-24w control arm (ARM C 'long control') or 0-8w control arm (ARM D 'short control') until 12 patients per arm are reached. The purpose of the control arms is to have a study population to compare the viral reservoir decay kinetics in the absence of vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0-24 week prime/boost regimen (ARM A)

Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen

Group Type EXPERIMENTAL

0-24 week prime/boost regimen

Intervention Type BIOLOGICAL

ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

0-8 week prime/boost regimen (ARM B)

Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen

Group Type EXPERIMENTAL

0-8 week prime/boost regimen

Intervention Type BIOLOGICAL

ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

Arm A control (ARM C)

Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.

Group Type NO_INTERVENTION

No interventions assigned to this group

Arm B control (ARM D)

Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0-24 week prime/boost regimen

ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

Intervention Type BIOLOGICAL

0-8 week prime/boost regimen

ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ARM A ARM B

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, aged 18-60 years
2. Confirmed HIV-1 seropositive documented in the past 6 months (by acute antiretroviral syndrome, p24 antigenemia and/or ELISA seroconversion)
3. Willing and able to give written informed consent for participation in the study
4. Willing and able to adhere to an effective HAART regimen for the duration of the study
5. Cluster of differentiation 4 (CD4)+ T cell count \> 350 cells/ml at screening and at the preceding clinic visit
6. No new AIDS-defining diagnosis or progression of HIV-related disease.
7. Haematological and biochemical laboratory parameters as follows: Haemoglobin \> 10g/dl, Platelets \> 100.000/dl, alanine aminotransferase (ALT) ≤ 2.5 x ULN, Creatinine ≤ 1.3 x upper limit of normal (ULN)
8. Serology: negative for hepatitis B surface antigen OR HbsAg positive with Hepatitis B Virus (HBV)-DNA \< 1000 copies/ml; negative for hepatitis C antibodies OR confirmed clearance of Hepatitis C Virus (HCV) infection (spontaneous or following treatment); negative syphilis serology or documented adequate treatment of syphilis if positive enzimeimmunoassay (EIA) Immonoglobulin G (IgG) or Treponema pallidum hemagglutination assay (TPHA)
9. Available for follow up for duration of study (screening + 72 weeks) and willing to comply with the protocol requirements
10. Women of child-bearing age must not be pregnant, not be planning a pregnancy or breast-feeding. Sexually active women must be willing to use an approved method of contraception from screening until 4 months after the second immunisation. Sexually active men in heterosexual relationships must be willing to use an approved method of contraception with their partners from screening until 4 months after the second immunisation.

Exclusion Criteria

1. Confirmed HIV-2 seropositive
2. Positive pregnancy test
3. Presence of Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) mutation in the screening genotype
4. Participation in another clinical trial within 12 weeks of study entry
5. History of autoimmune disease other than HIV-related auto-immune disease.
6. History or clinical manifestations of any physical or psychiatric disorder which could impair the subject's ability to complete the study
7. History of anaphylaxis or severe adverse reaction to vaccines
8. Previous immunisation with any experimental immunogens
9. Receipt of blood products within 6 months of study entry
10. Treatment for cancer or lymphoproliferative disease within 1 year of study entry
11. Receipt of vaccines other than Hepatitis B vaccine within 2 weeks of study entry or planned receipt within 2 weeks of vaccination
12. Any other prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study
13. Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No